{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:58:33Z","timestamp":1786985913730,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI152980"],"award-info":[{"award-number":["U01 AI152980"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cct.2025.107875","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T18:11:35Z","timestamp":1741457495000},"page":"107875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial"],"prefix":"10.1016","volume":"152","author":[{"given":"Pawandeep","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelia H.","family":"Chaisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zana Wangari","family":"Kiragu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praewpannarai","family":"Buddadhumaruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana F.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika J.","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Arbeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle Bliss","family":"Fetalvero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa Binh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhung Viet","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Eisenach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole D.","family":"Mitnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Tarcela S.","family":"Gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo E.","family":"Vel\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.107875_bb0005","series-title":"Global Tuberculosis Report 2024","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.cct.2025.107875_bb0010","series-title":"WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment - Drug-Resistant Tuberculosis Treatment 2022 Update","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.cct.2025.107875_bb0015","series-title":"Key Updates to the Treatment of Drug-Resistant Tuberculosis: Rapid Communication, June 2024","author":"World Health Organization","year":"2024"},{"issue":"7","key":"10.1016\/j.cct.2025.107875_bb0020","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1128\/AAC.00105-15","article-title":"Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"17","key":"10.1016\/j.cct.2025.107875_bb0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.107875_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1745-6215-14-88","article-title":"Randomized clinical trials to identify optimal antibiotic treatment duration","volume":"14","author":"Horsburgh","year":"2013","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.cct.2025.107875_bb0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/1740774518778027","article-title":"Rethinking non-inferiority: a practical trial design for optimising treatment duration","volume":"15","author":"Quartagno","year":"2018","journal-title":"Clin. Trials"},{"issue":"11","key":"10.1016\/j.cct.2025.107875_bb0040","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.cct.2025.107875_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067030","article-title":"Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients","volume":"8","author":"Jawahar","year":"2013","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.cct.2025.107875_bb0050","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.cct.2025.107875_bb0055","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2025.107875_bb0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"10150","key":"10.1016\/j.cct.2025.107875_bb0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cct.2025.107875_bb0070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02402-16","article-title":"Delamanid kills dormant mycobacteria in vitro and in a Guinea pig model of tuberculosis","volume":"61","author":"Chen","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.cct.2025.107875_bb0075","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/AAC.01418-13","article-title":"Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug","volume":"58","author":"McLeay","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.cct.2025.107875_bb0080","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4269\/ajtmh.1974.23.1097","article-title":"Pharmacologic studies of clofazimine","volume":"23","author":"Levy","year":"1974","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.cct.2025.107875_bb0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/03602539508994208","article-title":"The pharmacology, metabolism, and chemistry of clofazimine","volume":"27","author":"O\u2019Connor","year":"1995","journal-title":"Drug Metab. Rev."},{"issue":"9","key":"10.1016\/j.cct.2025.107875_bb0090","article-title":"Population pharmacokinetics and pharmacodynamics of investigational regimens\u2019 drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial","volume":"11","author":"Nyang\u2019wa","year":"2021","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.cct.2025.107875_bb0095","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.107875_bb0100","unstructured":"Unpublished work. Delamanid 300mg QD Dose Justification."},{"key":"10.1016\/j.cct.2025.107875_bb0105","series-title":"The NIX-TB Trial of Pretomanid, Bedaquiline and Linezolid to Treat XDR-TB [Abstract 80LB]. Seattle, WA","author":"Conradie","year":"2017"},{"issue":"2","key":"10.1016\/j.cct.2025.107875_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/26.2.227","article-title":"In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis","volume":"26","author":"Yew","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cct.2025.107875_bb0115","author":"Novartis Pharmaceuticals Corporation"},{"key":"10.1016\/j.cct.2025.107875_bb0120","series-title":"MGIT\u2122 Procedure Manual","first-page":"1","author":"Siddiqi","year":"2006"},{"issue":"7","key":"10.1016\/j.cct.2025.107875_bb0125","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cct.2025.107875_bb0130","series-title":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1","author":"National Institute of Allergy and Infectious Diseases","year":"2017"},{"issue":"1","key":"10.1016\/j.cct.2025.107875_bb0135","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/s41467-021-22833-6","article-title":"Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens","volume":"12","author":"Walter","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cct.2025.107875_bb0140","author":"CTEP"},{"key":"10.1016\/j.cct.2025.107875_bb0145","author":"Phillips"},{"key":"10.1016\/j.cct.2025.107875_bb0150","series-title":"Global Tuberculosis Report 2022","author":"World Health Organization","year":"2022"},{"issue":"13","key":"10.1016\/j.cct.2025.107875_bb0155","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2025.107875_bb0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.cct.2025.107875_bb0165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/3001616","article-title":"Some methods for strengthening the common \u03c72 tests","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.cct.2025.107875_bb0170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2307\/3001775","article-title":"Tests for linear trends in proportions and frequencies","volume":"11","author":"Armitage","year":"1955","journal-title":"Biometrics"},{"issue":"7","key":"10.1016\/j.cct.2025.107875_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002850","article-title":"Designing noninferiority tuberculosis treatment trials: identifying practical advantages for drug regimens with acceptable effectiveness","volume":"16","author":"Olliaro","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.cct.2025.107875_bb0180","series-title":"Handbook of Methods for Designing and Monitoring Dose Finding Trials","author":"O\u2019Quigley","year":"2017"},{"issue":"14","key":"10.1016\/j.cct.2025.107875_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12916-016-0597-3","article-title":"A new trial design to accelerate tuberculosis drug development: the phase IIC selection trial with extended post-treatment follow-up (STEP)","volume":"23","author":"Phillips","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.cct.2025.107875_bb0190","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"U.S. Department of Health and Human Services, NIH, National Cancer Institute","year":"2017"},{"issue":"1","key":"10.1016\/j.cct.2025.107875_bb0195","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1056\/NEJMc2404644","article-title":"Transmission as a key driver of resistance to the new tuberculosis drugs","volume":"392","author":"Goig","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:29:48Z","timestamp":1777793388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":39,"alternative-id":["S1551714425000692"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.107875","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.107875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107875"}}